From the Molecular Therapy Journal:
The gene therapy treatment Glybera has recently received marketing authorization in the European Union, representing the first such product to reach commercialization in the Western World. Glybera is an adeno-associated viral vector engineered to deliver to patients a therapeutic gene that can correct a rare genetic disorder of fat metabolism. While this approval represents an encouraging milestone for those developing gene and cell therapies, the regulatory approval process was not without controversy and setbacks. In this podcast, we have invited several leaders in the field of gene and cell therapies to discuss the challenges facing the field.
Seppo Yla-Herttuala, MD, PhD, FESC, Professor of Molecular Medicine, A.I.Virtanen Institute, University of Eastern Finland; Founder of Ark Therapeutics Group Plc; Past President of the European Society of Gene and Cell Therapy (2011-2012)
Fulvio Mavilio, PhD, Genethon
Barry Byrne, MD, PhD, University of Florida Powell Gene Therapy Center